Three U.S. pharmaceutical companies could expand after they received $93 million in funding from Rusnano, a Russian state technology firm, and various investors. Reuters reports that researchers with the three U.S. pharmaceutical businesses – Marinus Pharmaceuticals, Lithera and Regado Biosciences – will use the funds to study treatments for diseases such as epilepsy.

Rusnano officials noted that they also planned to make future investments in U.S. pharmaceutical companies. Around $760 million will be spent to fund research completed by U.S. healthcare and pharmaceutical firms, and Rusnano administrators said the American businesses could develop new drugs for the Russian market.

Tonix Pharmaceuticals, a specialty firm that develops treatments for central nervous system conditions, could also impact the U.S. economy over the next few years. Company leaders announced that they raised $1 million in gross proceeds from a private placement offering with venture capital firm Technology Partners. The additional funds will be used to help the firm develop new treatments, and the company could target new pharmaceutical professionals to provide extra assistance.

Content provided by executive search organization, MRINetwork.

In the News…

Paying Attention to Retention You've likely started to see a shift in headlines. No longer focused on what we have been through, the new emphasis is on what’s to come. Though it… Read More »

Job Application Process: Stay Sane The Job Application Process Can Be Frustrating. Here's How to Stay Sane The job application process is hardly ever easy. After all, it can sometimes… Read More »

The No. 1 recruitment metric employers track when assessing a new hire’s effectiveness After completing multiple rounds of interviews and presenting a job offer to a promising candidate, the work has in many ways just begun. Now that th… Read More »

Craft a Change Narrative How to Craft a Strong Change Narrative for Your Company When your company is undergoing major change, it can be a tough transition for everyone, e… Read More »

More News